PDCD1 and gastric cancer: Immune checkpoint inhibitors (ICI), represented by antibodies targeting programmed cell death protein-1 (PD-1), or PD-1 ligand 1 (PD-L1), have revolutionized the treatment strategy of advanced gastric cancer (2).